FDA rejects Navidea product on manufacturing issues; Whistleblower program in India a flop;

> Navidea Biopharmaceuticals says problems with its contract manufacturer led the FDA to reject its application for Lymphoseek, its radioactive tracing agent. Story

> Alan Cassels of the University of Victoria thinks Canadian regulators are so secretive about inspections of foreign plants that citizens cannot be sure of the safety of the drugs they receive. Story

> In a joint venture with AstraZeneca's ($AZN) biologics unit MedImmune, Chinese drugmaker WuXi AppTec will provide manufacturing, preclinical and clinical trials for MedImmune's antibody therapeutic for autoimmune and inflammatory diseases for the Chinese market. Story

> Indian drugmaker Biocon is looking to expand with a plant near Ahmedabad, Gujarat, India. Item

>  Boehringer Ingelheim has established a fully disposable setup and operational approach for disposable technologies as part of its drug development and manufacturing network that it believes will shorten turnaround times. Item

And Finally... A program set up in India in 2009 that would reward whistleblowers for offering up information about companies making fake or substandard drugs and selling them to the government has yet to result in one credible case, the Drug Controller General of India claims. Story

Suggested Articles

A biotech that worked with a nutritional products maker on the API for its clinical-stage radiation drug, is buying all of the manufacturing know-how.

Merck KGaA is selling a manufacturing site and its Allergopharma allergy drug business as it focuses on newer meds.

In a first, the FDA and Indian oversight agencies worked together to block illegal drugs from entering the U.S.